Pharma raises its bet on biotech

This week, we are revisiting a favorite episode. The natural diamond industry is facing an existential threat: lab-grown diamonds. They are chemically and physically identical to natural stones but they are a fraction of the price. Eleanor Olcott, the FT’s China technology corres ...  Show more

Introducing Opus Dei, a new season of Untold from the Financial Times. Host Antonia Cundy uncovers the cultural and political influence of a controversial Catholic organisation in America. Opus Dei exists to help people get closer to God, but some members say they found other age ...  Show more

Ireland-based biopharmaceutical company Jazz Pharmaceuticals buys the biggest acquisition in the cannabis industry to date after agreeing to buy GW Pharmaceuticals for $7.2 billion last week. Learn more about your ad-choices at https://www.iheartpodcastnetwork.comSee omnystudio.c ...  Show more

Netflix stock dropped after the company posted disappointing subscriber growth and earnings for the latest quarter. Plus results from Snap and Texas Instruments. And Institutional Investor’s Top-Rated Biotech Analyst breaks down the outlook for companies racing to bring a coro ...

Bloomberg BNA's Eleanor Tyler joins Tom Keene and Mike McKee to discuss pharmaceutical mergeres, tax inversions, drug pricing, and the renewed efforts by the Federal Trade Commission to regulate an increasingly complicated industry. Learn more about your ad-choices at https://www ...  Show more

Karen Ubelhart, Senior Industrials analyst for Bloomberg Intelligence, on 3M and Caterpillar earnings. Ellen Wald, President of Transversal Consulting and a Bloomberg Opinion contributor, on why the oil crisis will spill over into midstream companies. Jim Paulsen, Chief Investmen ...  Show more